

# Joel W Hay

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4534610/publications.pdf>

Version: 2024-02-01

136  
papers

5,004  
citations

117625

34  
h-index

98798

67  
g-index

141  
all docs

141  
docs citations

141  
times ranked

6095  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Behavioral Interventions on Inappropriate Antibiotic Prescribing Among Primary Care Practices. JAMA - Journal of the American Medical Association, 2016, 315, 562.	7.4	663
2	Effectiveness of a lifestyle intervention in promoting the well-being of independently living older people: results of the Well Elderly 2 Randomised Controlled Trial. Journal of Epidemiology and Community Health, 2012, 66, 782-790.	3.7	327
3	Examining the Value and Quality of Health Economic Analyses: Implications of Utilizing the QHES. Journal of Managed Care Pharmacy, 2003, 9, 53-61.	2.2	260
4	Development and Validation of a Grading System for the Quality of Cost-Effectiveness Studies. Medical Care, 2003, 41, 32-44.	2.4	253
5	Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 1992, 14, 309-317.	2.2	222
6	Costs of Necrotizing Enterocolitis and Cost-Effectiveness of Exclusively Human Milk-Based Products in Feeding Extremely Premature Infants. Breastfeeding Medicine, 2012, 7, 29-37.	1.7	176
7	Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Reportâ€™Part II. Value in Health, 2010, 13, 8-13.	0.3	120
8	Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 1992, 14, 318-327.	2.2	107
9	Evaluation of Strategies for Use of Acellular Pertussis Vaccine in Adolescents and Adults: A Cost-Benefit Analysis. Clinical Infectious Diseases, 2004, 39, 20-28.	5.8	107
10	Cost-Effectiveness of Preventive Occupational Therapy for Independent-Living Older Adults. Journal of the American Geriatrics Society, 2002, 50, 1381-1388.	2.6	106
11	Cost-Effectiveness of Pravastatin in Secondary Prevention of Coronary Artery Disease**This study was supported by Bristol-Myers Squibb, Plainsboro, New Jersey.. American Journal of Cardiology, 1996, 78, 409-414.	1.6	99
12	Medical costs of coronary artery disease in the United States. American Journal of Cardiology, 1990, 65, 432-440.	1.6	93
13	Antidepressant Use in Geriatric Populations: The Burden of Side Effects and Interactions and Their Impact on Adherence and Costs. American Journal of Geriatric Psychiatry, 2011, 19, 211-221.	1.2	88
14	Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Reportâ€™Part I. Value in Health, 2010, 13, 3-7.	0.3	81
15	Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective: The ISPOR Drug Cost Task Force Reportâ€™Part VI. Value in Health, 2010, 13, 28-33.	0.3	80
16	Pharmacoeconomics of Lipid-Lowering Agents for Primary and Secondary Prevention of Coronary Artery Disease. Pharmacoeconomics, 1999, 15, 47-74.	3.3	77
17	Using Conjoint Analysis to Assess Depression Treatment Preferences Among Low-Income Latinos. Psychiatric Services, 2004, 55, 934-936.	2.0	71
18	Long term healthcare costs of infants who survived neonatal necrotizing enterocolitis: a retrospective longitudinal study among infants enrolled in Texas Medicaid. BMC Pediatrics, 2013, 13, 127.	1.7	71

#	ARTICLE	IF	CITATIONS
19	An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. <i>American Journal of Cardiology</i> , 1991, 67, 789-796.	1.6	69
20	The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: A propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database. <i>American Heart Journal</i> , 2007, 154, 267-277.	2.7	63
21	Cost-Effectiveness Analysis of Collaborative Care Management of Major Depression among Low-Income, Predominantly Hispanics with Diabetes. <i>Value in Health</i> , 2012, 15, 249-254.	0.3	58
22	Physician-induced demand. <i>Journal of Health Economics</i> , 1982, 1, 231-244.	2.7	57
23	A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2016, 63, 1495-1504.	5.8	53
24	Effectiveness of Collaborative Care in Addressing Depression Treatment Preferences Among Low-Income Latinos. <i>Psychiatric Services</i> , 2010, 61, 1112-1118.	2.0	52
25	A US Population Health Survey on the Impact of COVID-19 Using the EQ-5D-5L. <i>Journal of General Internal Medicine</i> , 2021, 36, 1292-1301.	2.6	51
26	A Review of the Economic Burden of Glioblastoma and the Cost Effectiveness of Pharmacologic Treatments. <i>Pharmacoeconomics</i> , 2014, 32, 1201-1212.	3.3	49
27	Cost-effectiveness analysis of lapatinib in HER2-positive advanced breast cancer. <i>Cancer</i> , 2009, 115, 489-498.	4.1	48
28	Cost Effectiveness of Tumour Necrosis Factor-?? Inhibitors as First-Line Agents in Rheumatoid Arthritis. <i>Pharmacoeconomics</i> , 2006, 24, 1221-1232.	3.3	47
29	Let Them Eat Cake: A Note on Comparing Alternative Models of the Demand for Medical Care. <i>Journal of Business and Economic Statistics</i> , 1984, 2, 279.	2.9	46
30	Cost-benefit analysis of Haemophilus influenzae type b prevention. <i>Pediatric Infectious Disease Journal</i> , 1990, 9, 246-251.	2.0	38
31	Cost-Effectiveness of Primary Implanted Cardioverter Defibrillator for Sudden Death Prevention in Congestive Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2004, 18, 161-170.	2.6	38
32	Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States. <i>Clinical Colorectal Cancer</i> , 2018, 17, e751-e761.	2.3	37
33	Cost-Effectiveness Analysis of Pharmaceutical Care in a Medicare Drug Benefit Program. <i>Value in Health</i> , 2003, 6, 425-435.	0.3	35
34	Asthma costs and utilization in a managed care organization. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 885-892.e5.	2.9	35
35	Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 132, 677-683.	1.4	32
36	Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States. <i>International Journal of Cardiology</i> , 2015, 181, 417-424.	1.7	32

#	ARTICLE	IF	CITATIONS
37	The Kaiser Permanente/USC Patient Consultation Study: Change in use and cost of health care services. <i>American Journal of Health-System Pharmacy</i> , 1998, 55, 2485-2499.	1.0	31
38	First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective. <i>Lung Cancer</i> , 2018, 123, 166-171.	2.0	31
39	The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States. <i>Neuro-Oncology</i> , 2013, 15, 1532-1542.	1.2	29
40	Panel 2: Methodological Issues in Conducting Pharmacoeconomic Evaluations—Modeling Studies. <i>Value in Health</i> , 1999, 2, 78-81.	0.3	28
41	Economic Considerations for Pertussis Booster Vaccination in Adolescents. <i>Pediatric Infectious Disease Journal</i> , 2005, 24, S127-S133.	2.0	28
42	Cost Effectiveness of Treating Low HDL-Cholesterol in the Primary Prevention of Coronary Heart Disease. <i>Pharmacoeconomics</i> , 2005, 23, 133-141.	3.3	28
43	Evaluation and review of pharmacoeconomic models. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 1867-1880.	1.8	27
44	Cost Effectiveness of Moderate to Severe Psoriasis Therapy with Etanercept and Ustekinumab in the United States. <i>Pharmacoeconomics</i> , 2013, 31, 823-839.	3.3	27
45	Cost-Effectiveness Analysis of Abiraterone and Sipuleucel-T in Asymptomatic Metastatic Castration-Resistant Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1417-1425.	4.9	27
46	Depression treatment preferences of older white and Mexican origin men. <i>General Hospital Psychiatry</i> , 2013, 35, 59-65.	2.4	26
47	Comparative Effectiveness of a Technology-Facilitated Depression Care Management Model in Safety-Net Primary Care Patients With Type 2 Diabetes: 6-Month Outcomes of a Large Clinical Trial. <i>Journal of Medical Internet Research</i> , 2018, 20, e147.	4.3	26
48	Cost-Effectiveness of a Technology-Facilitated Depression Care Management Adoption Model in Safety-Net Primary Care Patients with Type 2 Diabetes. <i>Value in Health</i> , 2018, 21, 561-568.	0.3	25
49	Lifestyle intervention for adults with spinal cord injury: Results of the USC—RLANRC Pressure Ulcer Prevention Study. <i>Journal of Spinal Cord Medicine</i> , 2019, 42, 2-19.	1.4	25
50	The Impact of Public Health Care Financing Policies on Private-Sector Hospital Costs. <i>Journal of Health Politics, Policy and Law</i> , 1983, 7, 945-952.	1.9	24
51	Understanding patient preferences and willingness to pay for hemophilia therapies. <i>Patient Preference and Adherence</i> , 2015, 9, 1623.	1.8	24
52	Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States. <i>Annals of Pharmacotherapy</i> , 2019, 53, 134-143.	1.9	24
53	Effects of ambulatory-care pharmacist consultation on mortality and hospitalization. <i>American Journal of Managed Care</i> , 2003, 9, 45-56.	1.1	24
54	Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report—Part IV. <i>Value in Health</i> , 2010, 13, 18-24.	0.3	22

#	ARTICLE	IF	CITATIONS
55	Estimating the association between metabolic risk factors and marijuana use in U.S. adults using data from the continuous National Health and Nutrition Examination Survey. <i>Annals of Epidemiology</i> , 2015, 25, 486-491.	1.9	22
56	Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon- $\beta$ 1a in Relapsing-Remitting Multiple Sclerosis. <i>CNS Drugs</i> , 2015, 29, 71-81.	5.9	22
57	A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2775-2787.	1.8	21
58	Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Managed Care Perspective: The ISPOR Drug Cost Task Force Reportâ€”Part III. <i>Value in Health</i> , 2010, 13, 14-17.	0.3	21
59	Ordinary Least Squares and Sample-Selection Models of Health-Care Demand: Monte Carlo Comparison. <i>Journal of Business and Economic Statistics</i> , 1987, 5, 499.	2.9	20
60	Behavioral Economics Interventions to Improve Outpatient Antibiotic Prescribing for Acute Respiratory Infections: a Cost-Effectiveness Analysis. <i>Journal of General Internal Medicine</i> , 2019, 34, 846-854.	2.6	20
61	Measuring the impact of patient counseling in the outpatient pharmacy setting: the research design of the Kaiser permanente/USC patient consultation study. <i>Clinical Therapeutics</i> , 1995, 17, 1188-1206.	2.5	19
62	Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: use of propensityâ€”score and instrumental variable methods to adjust for treatmentâ€”selection bias. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 470-484.	1.9	19
63	Implementing trials of complex interventions in community settings: The USCâ€”Rancho Los Amigos Pressure Ulcer Prevention Study (PUPS). <i>Clinical Trials</i> , 2014, 11, 218-229.	1.6	19
64	Cost Impact of Diagnostic Imaging for Lower Extremity Peripheral Vascular Occlusive Disease. <i>Value in Health</i> , 2009, 12, 262-266.	0.3	18
65	Cost-Effectiveness Analysis of the Bivalent and Quadrivalent Human Papillomavirus Vaccines from a Societal Perspective in Colombia. <i>PLoS ONE</i> , 2013, 8, e80639.	2.5	17
66	Economical comparison of APCC vs. rFVIIa for mildâ€”toâ€”moderate bleeding episodes in haemophilia patients with inhibitors. <i>Haemophilia</i> , 2011, 17, e969-74.	2.1	16
67	Implementation and Outcomes of Commercial Disease Management Programs in the United States: The Disease Management Outcomes Consolidation Survey. <i>Disease Management: DM</i> , 2005, 8, 253-264.	1.0	15
68	A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma. <i>Journal of Asthma</i> , 2019, 56, 872-881.	1.7	15
69	Early onset sepsis calculator-based management of newborns exposed to maternal intrapartum fever: a cost benefit analysis. <i>Journal of Perinatology</i> , 2019, 39, 571-580.	2.0	15
70	Econometric issues in modeling the costs of AIDS. <i>Health Policy</i> , 1989, 11, 125-145.	3.0	14
71	Economic Modeling and Sensitivity Analysis. <i>Value in Health</i> , 1998, 1, 187-193.	0.3	14
72	Where's the Value in Health Care?. <i>Value in Health</i> , 2006, 9, 141-143.	0.3	14

#	ARTICLE	IF	CITATIONS
73	Cost-effectiveness of rivaroxaban versus warfarin for treatment of nonvalvular atrial fibrillation in patients with worsening renal function. <i>International Journal of Cardiology</i> , 2019, 282, 53-58.	1.7	14
74	Cost-effectiveness of bezlotoxumab and fidaxomicin for initial <i>Clostridioides difficile</i> infection. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1448-1454.	6.0	14
75	Cost effectiveness of methylphenidate versus AMP/DEX mixed salts for the first-line treatment of ADHD. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2004, 4, 625-634.	1.4	13
76	Cost-Effectiveness Analysis of Rizatriptan and Sumatriptan versus Cafergot?? in the Acute Treatment of Migraine. <i>CNS Drugs</i> , 2005, 19, 635-642.	5.9	13
77	Cost and resource utilization comparisons of second-generation antihistamines vs. montelukast for allergic rhinitis treatment. <i>Allergy and Asthma Proceedings</i> , 2009, 30, 634-642.	2.2	13
78	Cost-Benefit Analysis of In-Hospital Influenza Vaccination of Postpartum Women. <i>Obstetrics and Gynecology</i> , 2012, 119, 306-314.	2.4	13
79	Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 267-283.	1.4	13
80	Prescriber preferences for behavioural economics interventions to improve treatment of acute respiratory infections: a discrete choice experiment. <i>BMJ Open</i> , 2016, 6, e012739.	1.9	13
81	Health Care Costs and Outcomes: How Should We Evaluate Real World Data?. <i>Value in Health</i> , 1999, 2, 417-419.	0.3	11
82	Appropriate Econometric Methods for Pharmacoeconometric Studies of Retrospective Claims Data: An Introductory Guide. <i>Journal of Managed Care Pharmacy</i> , 2005, 11, 344-348.	2.2	11
83	Using Pharmacoeconomics to Value Pharmacotherapy. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 197-200.	4.7	11
84	Efficacy of Bypassing Agents in Patients With Hemophilia and Inhibitors: A Systematic Review and Meta-Analysis. <i>Clinical Therapeutics</i> , 2012, 34, 434-445.	2.5	11
85	Hospital cost drivers: an evaluation of 1998-2001 state-level data. <i>American Journal of Managed Care</i> , 2003, 9 Spec No 1, SP13-24.	1.1	11
86	Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: An Industry Perspective: The ISPOR Drug Cost Task Force Reportâ€”Part V. <i>Value in Health</i> , 2010, 13, 25-27.	0.3	10
87	Systematic literature review of economics analysis on treatment of mild-to-moderate bleeds with aPCC versus rFVIIa. <i>Journal of Medical Economics</i> , 2011, 14, 516-525.	2.1	9
88	Costâ€”Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderateâ€”Severe Crohn's Disease in Biologicâ€”Naïve Patients. <i>Pharmacotherapy</i> , 2019, 39, 118-128.	2.6	9
89	Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S. <i>General Dentistry</i> , 2010, 58, 484-92; quiz 493-4.	0.4	9
90	Cost and Utilization Impacts of Oral Antihistamines in the California Medi-Cal Program. <i>Value in Health</i> , 2005, 8, 506-516.	0.3	8

#	ARTICLE	IF	CITATIONS
91	A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2016, 22, 149-157.	0.9	8
92	Now Is the Time for Transparency in Value-Based Healthcare Decision Modeling. <i>Value in Health</i> , 2019, 22, 564-569.	0.3	8
93	Costs of second-generation antihistamines in the treatment of allergic rhinitis: US perspective. <i>Current Medical Research and Opinion</i> , 2009, 25, 1421-1431.	1.9	7
94	Cost-benefit analysis of hospital based postpartum vaccination with combined tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap). <i>Vaccine</i> , 2013, 31, 2558-2564.	3.8	7
95	Neonates with mild hypoxic-ischaemic encephalopathy receiving supportive care versus therapeutic hypothermia in California. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2021, , fetalneonatal-2021-322250.	2.8	7
96	Quality of Life in the Swedish General Population During COVID-19 - Based on pre- and post-pandemic outbreak measurement. <i>Nordic Journal of Health Economics</i> , 2021, 9, 56-73.	0.2	7
97	Risk of all-cause hospitalization in COPD patients initiating long-acting or short-acting beta agonist therapy. <i>Journal of Medical Economics</i> , 2013, 16, 1082-1088.	2.1	6
98	Outcomes and Utilization of Adjuvant Chemotherapy for Stage II Colon Cancer in the Oxaliplatin Period. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 428-434.	1.3	6
99	Cost-Effectiveness Analysis of Four Common Diagnostic Methods for <i>Clostridioides difficile</i> Infection. <i>Journal of General Internal Medicine</i> , 2020, 35, 1102-1110.	2.6	6
100	Commentary on Knight <i>et al.</i> : A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors. <i>Haemophilia</i> , 2010, 16, 366-368.	2.1	5
101	There is Insufficient Evidence to Support a Causal Relationship Between Chili Pepper Consumption and Mortality. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1864.	2.8	5
102	Reconstruction After Salvage Total Laryngectomy: A Cost-effectiveness Analysis. <i>Otolaryngology - Head and Neck Surgery</i> , 2021, 164, 139-145.	1.9	5
103	Where Do We Go From Here? A Framework for Using Susceptible-Infectious-Recovered Models for Policy Making in Emerging Infectious Diseases. <i>Value in Health</i> , 2021, 24, 917-924.	0.3	5
104	The cost effectiveness of cardiovascular medicines. <i>Current Atherosclerosis Reports</i> , 2005, 7, 79-80.	4.8	4
105	INCREMENTAL EXPENDITURE OF BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC TREATMENT USING INSTRUMENTAL VARIABLES IN PANEL DATA. <i>Health Economics (United Kingdom)</i> , 2013, 22, 807-823.	1.7	4
106	Factors Associated with Failure to Achieve SVR in Hepatitis C Genotype 3 Patients Within an Integrated Care Delivery System. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2015, 21, 641-647.	0.9	4
107	Diagnosing newborns with suspected mitochondrial disorders: an economic evaluation comparing early exome sequencing to current typical care. <i>Genetics in Medicine</i> , 2021, 23, 1854-1863.	2.4	4
108	Effects of fluoride and regular dental care on personal dental expenditures of young adults in Finland. <i>Community Dentistry and Oral Epidemiology</i> , 1982, 10, 15-22.	1.9	3

#	ARTICLE	IF	CITATIONS
109	Cost of lipid-lowering statin drugs. American Journal of Cardiology, 1996, 77, 225-226.	1.6	3
110	Pharmacoeconomics: Identifying the Issues Overview and Advisory Panel Report Summary. Value in Health, 1999, 2, 67-72.	0.3	3
111	An economic cost analysis of oral ganciclovir prophylaxis for the prevention of CMV disease. , 2000, 17, 911-919.		3
112	Pharmacoeconomic Guidelines: Where Do We Go from Here?. Value in Health, 2001, 4, 211.	0.3	3
113	Bypass therapy assay testing as a strategy to reduce costs for treatment of haemophilia patients with inhibitors. Haemophilia, 2013, 19, 711-719.	2.1	3
114	Promise of Precision Medicine. JAMA - Journal of the American Medical Association, 2015, 314, 1752.	7.4	2
115	Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab. Cost Effectiveness and Resource Allocation, 2018, 16, 30.	1.5	2
116	Medicare Pricing Mechanisms for Physician Services: An Overview of Alternative Approaches. Medical Care Review, 1986, 43, 59-100.	0.9	1
117	Comment: Evaluation of Pharmacoeconomic Studies: Utilization of a Checklist. Annals of Pharmacotherapy, 1994, 28, 539-539.	1.9	1
118	Introduction to the ISPOR Lipid Conference. Value in Health, 1998, 1, 95-99.	0.3	1
119	A Direction for Value in Health. Value in Health, 1998, 1, 149-154.	0.3	1
120	Commentary: Pharmacoeconomics and Outcomes Research: Expanding the Healthcare "Outcomes" Market. Value in Health, 2000, 3, 181-185.	0.3	1
121	The Application of Cost-Effectiveness and Cost-Benefit Analysis to Pharmaceuticals. , 2005, , 225-248.		1
122	Medicare Coverage and Reimbursement of Outpatient Prescription Drugs in the US. Applied Health Economics and Health Policy, 2005, 4, 9-14.	2.1	1
123	Comparing Patient Access to Pharmaceuticals in the UK and US. Applied Health Economics and Health Policy, 2006, 5, 269-270.	2.1	1
124	A six-year study of diagnostic lower extremity imaging practice patterns and outcomes in the Veterans Affairs health care system. International Journal of Angiology, 2008, 17, 78-82.	0.6	1
125	Prices, regulation and innovation in pharmaceuticals and biotechnology. Research in Human Capital and Development, 2007, , 81-99.	0.1	1
126	Marijuana Use in Models for Health Outcomes. American Journal of Medicine, 2015, 128, e23.	1.5	1



#	ARTICLE	IF	CITATIONS
127	Hypertension and Unlikely Causality in the Association Between Soft Drink Consumption and Mortality. <i>JAMA Internal Medicine</i> , 2020, 180, 335.	5.1	1
128	Characterizing the Validity and Real-World Utility of Health Technology Assessments in Healthcare: Future Directions Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modelling". <i>International Journal of Health Policy and Management</i> , 2020, 9, 352-355.	0.9	1
129	The ISPOR Lipid Conference: Pharmacoeconomics and Outcomes Modeling Issues. <i>Value in Health</i> , 1998, 1, 155-158.	0.3	0
130	From Research into Practice: How Should Healthcare Organizations/Governments Decide about Lipid Therapy and Who Will Pay? Reactor Panel and Open Forum. <i>Value in Health</i> , 1998, 1, 243-250.	0.3	0
131	Novel methods of measuring clinical outcomes from psoriasis and psoriatic arthritis clinical trials. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 545-558.	1.4	0
132	A Special Commemorative Issue Honoring William S. Comanor and 50 Years of Pharmaceutical Economics. <i>International Journal of the Economics of Business</i> , 2015, 22, 165-168.	1.7	0
133	Consistent estimation of polychotomous treatment effects with selection-bias and unobserved heterogeneity using panel data correlated random coefficients model. <i>Health Services and Outcomes Research Methodology</i> , 2018, 18, 75-95.	1.8	0
134	The Assessment of Different Diets and Mortality Fails to Address Unmeasured Confounding. <i>JAMA Internal Medicine</i> , 2021, 181, 137.	5.1	0
135	Current Issues in Pharmacoeconomic Modeling. <i>The Journal of Health Technology Assessment</i> , 2014, 2, 6-9.	0.2	0
136	Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysis. <i>BMC Urology</i> , 2022, 22, 76.	1.4	0